Breaking News Instant updates and real-time market news.

GSK

GlaxoSmithKline

$38.11

-0.34 (-0.88%)

, INVA

Innoviva

$10.91

-0.15 (-1.36%)

07:06
11/21/16
11/21
07:06
11/21/16
07:06

GlaxoSmithKline files regulatory submission for FF/UMEC/VI

GlaxoSmithKline (GSK) and Innoviva (INVA) announced the filing by GSK of a regulatory submission with the US FDA for the once-daily, closed triple combination therapy fluticasone furoate/umeclidinium/vilanterol for patients with chronic obstructive pulmonary disease. This follows the announcement earlier this year of plans to bring forward the timing of the U.S. filing from the first half of 2018. The closed triple combination therapy comprises three medicines: fluticasone furoate, an inhaled corticosteroid, umeclidinium, a long-acting muscarinic antagonist and vilanterol, a long- acting beta2-adrenergic agonist, delivered once-daily in GSK's Ellipta dry powder inhaler. The US regulatory submission of the closed triple therapy comprises a New Drug Application for the maintenance treatment of patients with COPD, including chronic bronchitis and emphysema. It is based on data from the closed triple combination therapy development programme, as well as data from studies with FF, UMEC and VI either alone or in combination. A regulatory filing in the EU is planned in the coming weeks and is expected to be followed by submissions in other countries beginning in 2017. The closed triple combination of FF/UMEC/VI is not approved for use anywhere in the world.

GSK

GlaxoSmithKline

$38.11

-0.34 (-0.88%)

INVA

Innoviva

$10.91

-0.15 (-1.36%)

  • 29

    Nov

GSK GlaxoSmithKline
$38.11

-0.34 (-0.88%)

09/23/16
09/23/16
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Morgan Stanley analyst Brian Nowak initiated Activision Blizzard (ATVI) and Electronic Arts (EA), both with Overweight ratings. The analyst is bullish on the digital gaming shift away from "units sold" to a business model based on users, engagement, and digital monetization. He sees digital in-game offerings resulting in recurring and growth user bases, increased per-game engagement, and further monetization opportunities. 2. AstraZeneca (AZN) and GlaxoSmithKline (GSK) both initiated with Overweight ratings by Piper Jaffray analyst Richard Purkiss. 3. Achillion (ACHN) initiated with an Outperform by Wedbush analyst Heather Behanna, who set a $13 price target on the shares. 4. Sysco (SYY) initiated with an Underweight at Barclays and $48 price target by analyst Karen Short. 5. Five Below (FIVE), Dollar Tree (DLTR) and Dollar General (DG) all initiated with Equal Weight ratings by Barclays analyst Karen Short. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
10/03/16
RBCM
10/03/16
NO CHANGE
Target $95
RBCM
Outperform
Gilead HIV franchise could see risk from competitor data, says RBC Capital
RBC Capital analyst Michael Yee said his conversations with doctors leads him to think two dolutegravir HIV "doublet" studies being conducted by GlaxoSmithKline (GSK) and ViiV Healthcare - Glaxo's joint venture with Pfizer (PFE) and Shionogi - are likely to work and present an underappreciated risk to Gilead's (GILD) HIV franchise. Talks with investors lead Yee to believe few are even aware of this risk and that the consensus view is underestimating the probability these non-inferiority trials will work. Arguing that the consensus view should factor in more conservative assumptions for Gilead's HIV business post 2018 due to this risk, Yee cut his price target on Gilead to $95 from $105, but keeps an Outperform rating on the shares.
10/06/16
PIPR
10/06/16
NO CHANGE
Target $46
PIPR
Overweight
Piper thinks Alnylam failure is positive for Ionis
Piper Jaffay analyst Joshua Schimmer thinks Alnylam Pharmaceuticals' (ALNY) "abrupt halt" of revusiran for TTR cardiomyopathy is likely a positive for Ionis Pharmaceuticals' (IONS) transthyretin program. The move "knocks out a competitive drug" while Ionis and GlaxoSmithKline (GSK) remain on their previously indicated timeline, Schimmer tells investors in a research note. The analyst at this point believes Alnylam's setback will be limited to revusiran and not read-through to other Gal-Nac programs or other TTR cardiomyopathy or polyneuropathy programs. He keeps an Overweight rating on Ionis with a $46 price target,
11/09/16
SBSH
11/09/16
NO CHANGE
SBSH
Citi sees Healthcare 'relief rally' after Trump win
Citi analyst Andrew Baum expects a "'relief rally" to drive near-term sector outperformance for names in the Healthcare space given the "inability of the Democrats to attain the Presidency, the House or Congress." Longer term, however, the analyst still sees "significant continued legislative risk" for pharma reimbursement. Baum prefers GlaxoSmithKline (GSK), AstraZeneca (AZN), Shire (SHPG) and Roche (RHHBY) among European majors and Bristol-Myers (BMY) and Eli Lilly (LLY) in the U.S.
INVA Innoviva
$10.91

-0.15 (-1.36%)

10/31/16
COWN
10/31/16
UPGRADE
Target $15
COWN
Outperform
Innoviva upgraded to Outperform from Market Perform at Cowen
Cowen analyst Tyler Van Buren upgraded Innoviva to Outperform and raised its price target to $15 from $13 citing valuation discount and said the commercial prospects for Breo and Anoro remain stronger than ever heading into next year.

TODAY'S FREE FLY STORIES

KFRC

Kforce

$25.50

0.3 (1.19%)

05:15
02/24/17
02/24
05:15
02/24/17
05:15
Downgrade
Kforce rating change  »

Kforce downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

INTU

Intuit

$120.70

1.27 (1.06%)

05:14
02/24/17
02/24
05:14
02/24/17
05:14
Upgrade
Intuit rating change  »

Intuit upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HPE

HP Enterprise

$24.66

-0.12 (-0.48%)

05:13
02/24/17
02/24
05:13
02/24/17
05:13
Downgrade
HP Enterprise rating change  »

HP Enterprise downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

W

Wayfair

$38.58

-2.68 (-6.50%)

05:13
02/24/17
02/24
05:13
02/24/17
05:13
Downgrade
Wayfair rating change  »

Wayfair downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HTGC

Hercules Capital

$14.94

-0.49 (-3.18%)

05:12
02/24/17
02/24
05:12
02/24/17
05:12
Downgrade
Hercules Capital rating change  »

Hercules Capital…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IVR

Invesco Mortgage

$15.57

0.08 (0.52%)

05:12
02/24/17
02/24
05:12
02/24/17
05:12
Downgrade
Invesco Mortgage rating change  »

Invesco Mortgage…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    May

REG

Regency Centers

$70.95

0.94 (1.34%)

, EQY

Equity One

$31.91

0.39 (1.24%)

04:55
02/24/17
02/24
04:55
02/24/17
04:55
Conference/Events
Equity One to host special shareholder meeting »

Special Shareholder…

REG

Regency Centers

$70.95

0.94 (1.34%)

EQY

Equity One

$31.91

0.39 (1.24%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Feb

  • 24

    Feb

MMM

3M

$187.19

1.15 (0.62%)

, BIOL

BIOLASE

$1.50

-0.02 (-1.32%)

04:55
02/24/17
02/24
04:55
02/24/17
04:55
Conference/Events
Chicago Dental Society to hold a meeting »

Chicago Dental Midwinter…

MMM

3M

$187.19

1.15 (0.62%)

BIOL

BIOLASE

$1.50

-0.02 (-1.32%)

COF

Capital One

$93.41

0.52 (0.56%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RIO

Rio Tinto

$42.51

-1.83 (-4.13%)

04:55
02/24/17
02/24
04:55
02/24/17
04:55
Conference/Events
Rio Tinto management to meet with Jefferies »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Feb

  • 26

    Feb

EQY

Equity One

$31.91

0.39 (1.24%)

, REG

Regency Centers

$70.95

0.94 (1.34%)

04:55
02/24/17
02/24
04:55
02/24/17
04:55
Conference/Events
Regency Centers to host special shareholder meeting »

Special Shareholder…

EQY

Equity One

$31.91

0.39 (1.24%)

REG

Regency Centers

$70.95

0.94 (1.34%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Feb

  • 24

    Feb

CASM

CAS Medical

$1.48

-0.01 (-0.67%)

04:55
02/24/17
02/24
04:55
02/24/17
04:55
Conference/Events
CAS Medical management to meet with Craig Hallum »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Feb

PBNC

Paragon Commercial

$50.50

-0.35 (-0.69%)

04:55
02/24/17
02/24
04:55
02/24/17
04:55
Conference/Events
Paragon Commercial management to meet with Sandler O'Neill »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Feb

SC

Santander Consumer

$14.33

-0.12 (-0.83%)

04:55
02/24/17
02/24
04:55
02/24/17
04:55
Conference/Events
Santander Consumer management to meet with Jefferies »

Meeting to be held in San…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Feb

ELNK

EarthLink

$5.85

0.04 (0.69%)

, WIN

Windstream

$7.29

0.07 (0.97%)

04:55
02/24/17
02/24
04:55
02/24/17
04:55
Conference/Events
Windstream to host special shareholder meeting »

Virtual Special…

ELNK

EarthLink

$5.85

0.04 (0.69%)

WIN

Windstream

$7.29

0.07 (0.97%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Feb

  • 24

    Feb

  • 01

    Mar

  • 06

    Mar

GIS

General Mills

$60.78

0.19 (0.31%)

, TSN

Tyson Foods

$62.82

-0.4 (-0.63%)

04:55
02/24/17
02/24
04:55
02/24/17
04:55
Conference/Events
The Consumer Analyst Group of New York to hold a conference »

2017 CAGNY Conference is…

GIS

General Mills

$60.78

0.19 (0.31%)

TSN

Tyson Foods

$62.82

-0.4 (-0.63%)

TWNK

Hostess Brands

$15.78

0.31 (2.00%)

MJN

Mead Johnson

$87.61

0.11 (0.13%)

K

Kellogg

$74.80

0.31 (0.42%)

MDLZ

Mondelez

$44.89

0.24 (0.54%)

INGR

Ingredion

$122.28

1.66 (1.38%)

LNCE

Snyder's-Lance

$39.60

0.17 (0.43%)

SYY

Sysco

$52.89

0.14 (0.27%)

JNJ

Johnson & Johnson

$120.90

2.18 (1.84%)

SJM

J.M. Smucker

$140.83

0.1 (0.07%)

MO

Altria Group

$74.46

0.86 (1.17%)

CPB

Campbell Soup

$59.06

-0.11 (-0.19%)

PEP

PepsiCo

$109.54

0.13 (0.12%)

CLX

Clorox

$135.83

-0.09 (-0.07%)

BG

Bunge

$80.05

0.61 (0.77%)

PG

Procter & Gamble

$91.13

-0.31 (-0.34%)

DANOY

Danone

$13.34

0.13 (0.98%)

SPB

Spectrum Brands

$137.26

0.97 (0.71%)

KO

Coca-Cola

$41.66

0.06 (0.14%)

IFF

International Flavors

$125.14

2.51 (2.05%)

STZ

Constellation Brands

$153.60

-6.6 (-4.12%)

NSRGY

Nestle

$74.20

0.4 (0.54%)

CHD

Church & Dwight

$49.62

-0.07 (-0.14%)

UN

Unilever; also tag UL

$46.58

-0.17 (-0.36%)

CL

Colgate-Palmolive

$74.44

0.95 (1.29%)

NWL

Newell Brands

$46.80

-0.26 (-0.55%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Feb

  • 24

    Feb

  • 27

    Feb

  • 09

    Mar

  • 14

    Mar

  • 15

    Mar

  • 19

    Mar

  • 27

    Mar

  • 09

    May

04:55
02/24/17
02/24
04:55
02/24/17
04:55
Conference/Events
CLSA to hold a forum »

Japan Forum is being held…

04:55
02/24/17
02/24
04:55
02/24/17
04:55
Conference/Events
CLSA financial tech analyst holds an analyst/industry conference call »

Financial Technology…

AGN

Allergan

$246.33

0.71 (0.29%)

, EDGE

Edge Therapeutics

$10.00

-0.27 (-2.63%)

04:55
02/24/17
02/24
04:55
02/24/17
04:55
Conference/Events
American Heart Association to hold a conference »

International Stroke…

AGN

Allergan

$246.33

0.71 (0.29%)

EDGE

Edge Therapeutics

$10.00

-0.27 (-2.63%)

AMGN

Amgen

$174.01

1.4 (0.81%)

ATRC

AtriCure

$17.35

0.13 (0.75%)

BMY

Bristol-Myers

$55.77

0.42 (0.76%)

DNA

Bought by RHHBY

MDCO

The Medicines Co.

$51.84

-0.38 (-0.73%)

MDT

Medtronic

$80.74

1.12 (1.41%)

MRK

Merck

$65.85

0.56 (0.86%)

PH

Parker-Hannifin

$153.70

-2.16 (-1.39%)

PTLA

Portola Pharmaceuticals

$32.16

0.02 (0.06%)

Q

QuintilesIMS

$78.12

0.77 (1.00%)

SSNLF

Samsung

SAY

Satyam

TWTR

Twitter

$16.03

-0.05 (-0.31%)

WTKWY

Wolters Kluwer

$40.39

0.502 (1.26%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

  • 27

    Feb

  • 27

    Feb

  • 28

    Feb

  • 28

    Feb

  • 28

    Feb

  • 28

    Feb

  • 02

    Mar

  • 07

    Mar

  • 08

    Mar

  • 09

    Mar

  • 15

    Mar

  • 17

    Mar

  • 19

    Mar

  • 21

    Mar

  • 28

    Mar

  • 01

    Apr

  • 04

    May

  • 10

    May

  • 27

    May

  • 14

    Jun

  • 24

    Jun

  • 19

    Jul

04:55
02/24/17
02/24
04:55
02/24/17
04:55
Conference/Events
Wells Fargo housing analyst holds an analyst/industry conference call »

Senior Housing Analyst…

NVO

Novo Nordisk

$35.78

0.53 (1.50%)

04:55
02/24/17
02/24
04:55
02/24/17
04:55
Conference/Events
Novo Nordisk management to meet with Jefferies »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Feb

  • 07

    Mar

KAR

KAR Auction

$44.50

-0.3 (-0.67%)

04:55
02/24/17
02/24
04:55
02/24/17
04:55
Conference/Events
KAR Auction management to meet with Jefferies »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Feb

  • 13

    Mar

  • 14

    Mar

  • 15

    Mar

04:55
02/24/17
02/24
04:55
02/24/17
04:55
General news
Consumer Sentiment Index to be reported at 10:00 »

February Consumer…

04:55
02/24/17
02/24
04:55
02/24/17
04:55
General news
New Home Sales to be reported at 10:00 »

January New Home Sales…

VWDRY

Vestas

$25.08

0.175 (0.70%)

04:55
02/24/17
02/24
04:55
02/24/17
04:55
Conference/Events
Vestas management to meet with JPMorgan »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Feb

HSIC

Henry Schein

$171.92

-0.72 (-0.42%)

04:55
02/24/17
02/24
04:55
02/24/17
04:55
Conference/Events
Henry Schein management to meet with Jefferies »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Feb

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.